Table 1

Baseline characteristics of study participants (n=135)

VariableMean (SD) or frequency (%)
Age (years)47.7 (13.7)
Sex: female (%)66 (49%)
PsA duration (years)4.7 (6.8)
No. of prior DMARDs (%)
 052 (38.5%)
 133 (24.5%)
 2+50 (37%)
No. of prior b/tsDMARD (%)
 090 (66.7%)
 119 (14.1%)
 213 (9.6%)
 3+13 (9.6%)
Tender joints (0–68)6.5 (5.5)
Swollen joints (0–66)4.7 (4.6)
Enthesitis (any)81 (60%)
SPARCC1.6 (1.7)
Dactylitis (any)39 (28.9%)
Dactylitis count0.5 (0.9)
PASI4.5 (5.6)
hsCRP7.6 (11.8)
DAPSA29.1 (18.8)
Pain (0–10)5.1 (2.4)
Patient global (0–10)5.2 (2.4)
Physician global (0–10)5.1 (1.7)
HAQ (0–3)0.7 (0.5)
Medications analysed for treatment outcomes
DAPSA change (n=87)Drug persistence (n=105)
csDMARD1113
 Methotrexate911
 Sulfasalazine22
Start ts/bDMARD*
 TNF inhibitor4144
 IL-17 inhibitor2837
 IL12/23 or IL-23 inhibitor11
 JAK inhibitor610
  • b/tsDMARD, biologic and targeted Disease-modifying antirheumatic drugs; csDMARD, conventional synthetic DMARD; DAPSA, Disease Activity Index for Psoriatic Arthritis; DMARDs, disease-modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire for rheumatoid arthritis; hsCRP, high-sensitivity C reactive protein; IL, Interleukin (IL); JAK, Janus Kinase; PASI, Psoriasis Area and Severity Index; SPARCC, Spondyloarthritis Research Consortium of Canada; TNF, Tumor Necrosis Factor.